Marc Tessier-Lavigne - 03 Jun 2025 Form 4 Insider Report for Denali Therapeutics Inc. (DNLI)

Reporting relationship: Director
Issuer ticker: DNLI
Reported as of: 03 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Jun 2025, 16:23:08 UTC
Prior SEC filing: 04 Jun 2024
Source filing: View source filing
Reporting owner signature: /s/ Tyler Nielsen, by power of attorney

Key filing fact

Marc Tessier-Lavigne filed Form 4 for Denali Therapeutics Inc. (DNLI) on 05 Jun 2025.

Key facts

This page summarizes Marc Tessier-Lavigne's Form 4 filing for Denali Therapeutics Inc. (DNLI).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 05 Jun 2025, 16:23.

Change

Previous filing in this sequence was filed on 04 Jun 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001437435 Primary reporting owner

Tessier-Lavigne Marc

Relationship: Director
Address: C/O DENALI THERAPEUTICS INC., 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Signature: /s/ Tyler Nielsen, by power of attorney
Signature date: 05 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

DNLI transaction

Common Stock

Award

Transaction value: $0
Shares: +6,037
Change %: +0.32%
Price: $0.000000
Shares after: 1,886,576
Date: 03 Jun 2025
Ownership: Direct
Footnotes: F1, F2

DNLI holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 78,848
Date: 03 Jun 2025
Ownership: The Tessier-Lavigne/Hynes Irrevocable Trust 1
Footnotes: F3

DNLI holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 79,173
Date: 03 Jun 2025
Ownership: The Tessier-Lavigne/Hynes Irrevocable Trust 2
Footnotes: F4

DNLI holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 78,848
Date: 03 Jun 2025
Ownership: The Tessier-Lavigne/Hynes Irrevocable Trust 3
Footnotes: F5

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

DNLI transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +18,111
Change %
Price: $0.000000
Shares after: 18,111
Date: 03 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 18,111
Exercise price: $13.93
Footnotes: F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.

Footnote F2

Includes 6,037 unvested RSUs.

Footnote F3

The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 1, for which the Reporting Person serves as trustee.

Footnote F4

The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 2, for which the Reporting Person serves as trustee.

Footnote F5

The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 3, for which the Reporting Person serves as trustee.

Footnote F6

100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.